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Emerging evidence indicates the pronounced role of inﬂammasome activation linked to reactive oxygen species (ROS) in the sterile
inﬂammatory response triggered by ischemia/reperfusion (I/R) injury. Ethyl pyruvate (EP) is an antioxidant and conveys
myocardial protection against I/R injury, while the exact mechanisms remain elusive. We aimed to investigate the eﬀect of EP
on myocardial I/R injury through mechanisms related to ROS and inﬂammasome regulation. The rats were randomly assigned
to four groups: (1) sham, (2) I/R-control (IRC), (3) EP-pretreatment + I/R, and (4) I/R + EP-posttreatment. I/R was induced by a
30min ligation of the left anterior descending artery followed by 4 h of reperfusion. EP (50mg/kg) was administered
intraperitoneally at 1 h before ischemia (pretreatment) or upon reperfusion (posttreatment). Both pre- and post-EP treatment
resulted in signiﬁcant reductions in myocardial infarct size (by 34% and 31%, respectively) and neutrophil inﬁltration.
I/R-induced myocardial expressions of NADPH oxidase-4, carnitine palmitoyltransferase 1A, and thioredoxin-interacting
protein (TXNIP) were mitigated by EP. EP treatment was associated with diminished inﬂammasome activation (NOD-like
receptor 3 (NLRP3), apoptosis-associated speck-like protein, and caspase-1) and interleukin-1β induced by I/R. I/R-induced
phosphorylation of ERK and p38 were also mitigated with EP treatments. In H9c2 cells, hypoxia-induced TXNIP and NLRP3
expressions were inhibited by EP and to a lesser degree by U0126 (MEK inhibitor) and SB203580 (p38 inhibitor) as well. EP’s
downstream protective mechanisms in myocardial I/R injury would include mitigation of ROS-mediated NLRP3 inﬂammasome
upregulation and its associated pathways, partly via inhibition of hypoxia-induced phosphorylation of ERK and p38.
1. Introduction
Timely restoration of coronary ﬂow is essential for myocar-
dial salvage and remains the cornerstone of therapies for
myocardial infarction. However, reperfusion inevitably
accompanies a speciﬁc, sterile inﬂammation that has been
extensively studied to be the principal cause of further
myocardial damage and dysfunction [1]. In that context,
emerging evidence indicates the role of inﬂammasome as
one of the key regulators of this inﬂammation-mediated
ischemia/reperfusion (I/R) injury [2].
The inﬂammasome is a multiprotein complex that
embodies caspase-1, apoptosis-associated speck-like protein
(ASC), and nucleotide-binding oligomerization domain-like
receptor with a pyrin domain (NLRP) [3]. As an integral
component of the inherent immune system, activation of
the inﬂammasome results in the production of potent
inﬂammatory cytokines, interleukin- (IL-) 1β and IL-18, that
promote further myocardial damage after I/R [4, 5]. In
addition, caspase-1 activation and inﬂammasome formation
lead to a distinct form of cell death called pyroptosis [5].
Accounting for its dominant role in mediating inﬂammation,
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experimental endeavors to ﬁnd therapies targeting the
inﬂammasome in neurodegenerative or metabolic disorders
have been made with some promising results [6]. Yet, evi-
dence regarding relevant therapies in myocardial I/R injury
is scarce.
Ethyl pyruvate (EP) is a stabilized ester form of the
innately existing antioxidant pyruvate [7, 8]. Accordingly,
in conjunction with its proven clinical safety, EP conveyed
beneﬁcial inﬂuences in various inﬂammatory diseases and
I/R injury of major organs [8]. In terms of myocardial I/R
injury, EP has been shown to exert potent myocardial protec-
tion that is retained even in a hyperglycemic condition [9],
which is known to abrogate the protective eﬃcacies of many
experimentally proven therapies [10]. However, the underly-
ing mechanisms remain obscure, which include EP’s eﬀects
of reactive oxygen species (ROS) scavenging and high mobil-
ity group box 1 inhibition leading to anti-inﬂammatory and
antiapoptotic eﬀects [11]. Considering that excessive ROS
production is a critical activator of the inﬂammasome [12],
EP’s protective eﬀects against myocardial I/R injury would
theoretically involve regulation of inﬂammasome activity,
which has not been examined heretofore.
This study was aimed at investigating the protective role
of EP against myocardial I/R injury and seeking for the
mechanistic insights with particular relevance to ROS and
inﬂammasome regulation.
2. Materials and Methods
2.1. Animal Preparation. All experiments were sanctioned by
the committee for the Care and Use of Laboratory Animals,
Yonsei University College of Medicine, and were executed
conforming to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(No. 85-23, 1996).
Male Sprague-Dawley rats (10–12 wk old, 250–300 g)
were anesthetized with Rompun (10mg/kg, Vial Korea) and
Zoletil 50 (30mg/kg, Virbac Korea) and were intubated for
mechanical ventilation. Normothermia (at around 37°C)
was maintained using an electric heating pad. Heparin
(200 IU/kg) was given before ischemia intravenously. The
right femoral artery was cannulated to monitor mean arterial
pressure (MAP). Heart rate (HR) was monitored by subcuta-
neous stainless steel electrodes.
2.2. Experimental Models and Study Groups. Myocardial I/R
injury was achieved by encircling the left anterior descending
coronary artery (LAD) with a 4-0 silk suture placed through a
left parasternal incision [13]. Ischemia was induced for
30min, conﬁrmed by ST elevation and regional cyanosis of
the myocardium, followed by 4h of reperfusion. In the sham
group, the same procedures were performed without LAD
ligation. MAP and HR were recorded at baseline, during
ischemia, and after reperfusion. EP (50mg/kg, Sigma-Al-
drich, St. Louis, MO) was administered 1 h before ischemia
or upon reperfusion via the tail vein, while the I/R-control
(IRC) group received an equivalent amount of 0.9% saline
(200μL).
The animals were randomly assigned into four groups:
(1) sham (n = 10), (2) IRC (n = 17), (3) EP-pretreatment +
I/R (EPpre) (n = 17), and (4) I/R+EP-posttreatment (EPpost)
(n = 17). Tissues were collected at the end of 4 h of
reperfusion.
2.3. Myocardial Infarct Size Determination. Upon 4h of
reperfusion, 1mL of 2% Evans blue dye was administered
intravenously while occluding the LAD again. Four to ﬁve
transverse sections (2mm thick) of the left ventricle were
obtained and incubated with 2% 2,3,5-triphenyltetrazolium
chloride (TTC) for 20min at 37°C, followed by 10min incu-
bation in 1% TTC. The area at risk was estimated as a per-
centage of the left ventricle showing the absence of blue
staining. The infarct borders were delineated, and the area
was quantiﬁed with ImageJ software. The infarct size was
determined as a percentage of the area at risk.
2.4. H&E Staining. After reperfusion, hearts were immedi-
ately excised, cross-sectioned, and ﬁxed with 10% buﬀered
formalin. Fixed tissue was then paraﬃn embedded and sec-
tioned (5μm) and stained with hematoxylin and eosin
(H&E). Five visual ﬁelds from each sample block (5 blocks/-
rat) were randomly chosen and examined by a blind observer
using a microscope (×400). A pathologist (E. Shin) who was
blinded to all information then evaluated the H&E stained
slides for neutrophilic inﬁltrate, hemorrhage, and acute myo-
cardial necrosis.
2.5. Immunohistochemistry. For analyzing the expression of
the NLRP3 inﬂammasome, paraﬃn-embedded sections from
each group were deparaﬃnized and rehydrated. Then, sec-
tions were microwaved in 0.01M citrate buﬀer, washed with
PBS for 15min, and subsequently treated with 5% BSA
blocking buﬀer for 30min at room temperature. Afterwards,
these sections were incubated with a primary antibody to
anti-NLRP3 (Abcam, UK) for 1 h at 37°C. After washing with
PBS for 3 times, a secondary antibody was added, and immu-
nostaining was performed using a DAB kit (Invitrogen,
Gibco, USA). The NLRP3-positive area was assessed using
ImageJ (US National Institute of Health, Bethesda, MD).
2.6. Immunoprecipitaion and Immunoblot Analysis. The left
ventricle containing the infarcted area and its neighboring
borders was procured. After measuring protein concentra-
tions, 1mg of protein from each cell lysate was immunopre-
cipitated using the appropriate primary antibodies and
protein G-agarose beads [14]. Proteins were separated on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and immunoblotted with anti-thioredoxin-interacting pro-
tein (TXNIP) (Santa Cruz Biotechnology Inc., CA, USA),
anti-caspase-1, anti-cleaved caspse-1 (Cell Signaling Tech-
nology, Beverly, MA), anti-carnitine palmitoyl transferase
1A (CTP1A), anti-NAPDH oxidase 4 (NOX4), anti-NLRP3,
anti-ASC, and anti-IL-1β (all Abcam, UK).
2.7. Cell Culture. H9c2 cardiomyocytes (ATCC, MD, USA)
were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum, 100U/mL peni-
cillin, and 100μg/mL streptomycin (Gibco, USA) at 37°C in
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95% humidiﬁed air plus 5% CO2. Cells were plated into 60 or
100mm tissue culture dishes with serum-free medium and
incubated under normoxic (5% CO2 in air) or hypoxic
(1% O2, 5% CO2, and 94% N2) conditions. Treatments
were as follows: EP (10mM), MEK inhibitor U0126
(20μM), or p38 inhibitor SB203580 (10μM) (Cell Signaling
Technology Inc.). We performed hypoxia-induced cellular
toxicity using EZ-Cytox-enhanced cell viability assay kit
(DoGeN, South Korea).
2.8. DNA Constructs and Transient Transfection. The plas-
mid constructs Myc-tagged TXNIP and GFP-tagged NLRP3
were from OriGene (Rocksille, MD, USA). pcDNA was from
Stratagene (La Jolla, CA, USA). Transfection was performed
with the TransIT-X2® Dynamic Delivery System (Mirus Bio
LLC, USA). In each transfection, 100 ng of expression
plasmids were used as indicated. After overnight recovery
from transfection, the cells were incubated under a hypoxic
condition for 24 h.
2.9. Statistical Analysis. All results were expressed as mean
± SD. Hemodynamic data were analyzed by repeated
measures of ANOVA. Other variables were analyzed by
two-way ANOVA. The P values of post hoc tests were
adjusted by Bonferroni’s methods. The statistical signiﬁcance
of cell examination was analyzed by Student’s t-test. Values
of P < 0 05 were considered statistically signiﬁcant.
3. Results
3.1. Hemodynamic Parameters. The trends of MAP and HR
over time were similar among the groups. MAPs recorded
during ischemia were signiﬁcantly lower compared to their
corresponding baseline values in all groups, while HR did
not show any signiﬁcant changes throughout the study
period (data not shown).
3.2. EP Attenuated Myocardial Infarction and Neutrophilic
Inﬁltration after I/R.Myocardial infarct size was signiﬁcantly
decreased in both EPpre and EPpost groups compared to those
in the IRC group by approximately 34% and 31%, respec-
tively (P < 0 05), without any signiﬁcant intergroup diﬀer-
ence between the EP-treatment groups (Figure 1(a)).
EP-treatment groups also displayed reductions in myo-
cardial neutrophilic inﬁltration, necrosis, and hemorrhage
when compared with the IRC group (Figure 1(b)).
3.3. EP Ameliorated Myocardial I/R-Induced Increase in
NLRP3 Expression. Using immunohistochemistry staining,
the NLRP3-positive myocardial area following I/R injury
was assessed. The amount of NLRP3 in the IRC group was
signiﬁcantly increased following I/R injury compared with
those in the sham group. Both EPpre and EPpost groups exhib-
ited signiﬁcantly lower NLRP3 expression than the IRC
group, without any signiﬁcant intergroup diﬀerence between
the EP-treatment groups. However, NLRP3 expression was
similar between the EPpre group and the sham group, while
it was signiﬁcantly increased in the EPpost group compared
with the sham group (Figure 2).
3.4. EP Attenuated the Activation of the NLRP3
Inﬂammasome and Subsequent Increase in IL-1β
Production following Myocardial I/R Injury. I/R injury signif-
icantly induced the activation of the NLRP3 inﬂammasome
(NLRP3, ASC, caspase-1, and cleaved caspase-1) and the
production of IL-1β compared to the Sham group. However,
these protein expressions could all be signiﬁcantly attenuated
by both EPpre and EPpost treatments compared to the IRC
group (Figure 3). The EPpre group exhibited signiﬁcantly
lower expressions of NLRP3, caspase-1, and cleaved
caspase-1 compared with the EPpost group, while the IL-1β








































Figure 1: EP attenuated myocardial infarction and apoptosis after I/R. Myocardial infarct size was determined as a percentage of the area at
risk using 2,3,5-triphenyltetrazolium chloride (a). Neutrophilic inﬁltrate, hemorrhage, and necrosis were assessed using hematoxylin and
eosin staining (b). EP, ethyl pyruvate; IRC, ischemia (30min)-reperfusion (4 h) without treatment; EPpre, EP (50mg/kg) treatment 1 h
before ischemia; EPpost, EP (50mg/kg) treatment upon reperfusion. AAR, area at risk/left ventricle. #P < 0 05 compared with the IRC
groups (n = 5, each).
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3.5. EP Attenuated Myocardial I/R-Induced Increases of
NOX4, CTP1A, and TXNIP. NOX4, CTP1A, and TXNIP
are known mediators linked to ROS formation and inﬂam-
masome activation. Following myocardial I/R injury, the
expression levels of NOX4, CTP1A, and TXNIP were signif-
icantly increased in the IRC group compared with those in
the sham group, while their elevations were signiﬁcantly mit-
igated by both EPpre and EPpost treatments compared to those
of the IRC group (P < 0 05) (Figure 4). NOX4 expression was
signiﬁcantly lower in the EPpre group than in the EPpost
group, while CTP1A and TXNIP levels were similar between
the EP-treatment groups.
3.6. EP Decreased Myocardial I/R-Induced ERK and p38
Phosphorylation. ROS and mitogen-activated protein kinase
(MAPK) have been shown to be closely interlinked mutually
and with the NLRP3 inﬂammasome as well [3, 15, 16].
P-ERK and P-p38 levels were increased in the IRC group
compared to those in the sham group. Both
EP-treatment groups exhibited signiﬁcantly decreased
ERK and p38 phosphorylation compared with the IRC
group (P < 0 05), without any intergroup (EPpre vs. EPpost)
diﬀerence (Figure 5).
3.7. EP Reduced Hypoxia-Induced TXNIP-NLRP3
Expressions and their Interaction Partly via ERK and p38
Pathway in H9c2 Cardiomyocytes. To conﬁrm whether the
chosen dose of EP (10mM) lacked cytotoxicity, we examined
H9c2 cardiomyocytes cultured for 24 h in the presence or
absence of EP under normoxic or hypoxic conditions.
10mM EP showed no cytotoxicity under both conditions in






















Figure 2: EP ameliorated myocardial I/R-induced increase in NLRP3 expression. Using immunohistochemistry staining, the NLRP3-positive
myocardial area following I/R injury was assessed. EP, ethyl pyruvate; NLRP3, nucleotide-binding oligomerization domain-like receptor with
a pyrin domain 3; IRC, ischemia (30min)-reperfusion (4 h) without treatment; EPpre, EP (50mg/kg) treatment 1 h before ischemia; EPpost, EP
(50mg/kg) treatment upon reperfusion. IRC, ischemia (30min)-reperfusion (4 h) without treatment in heart. ∗P < 0 05 compared with the
sham group; #P < 0 05 compared with the IRC groups (n = 5, each).


































Figure 3: EP attenuated the activation of the NLRP3 inﬂammasome and subsequent increase in IL-1β production following myocardial I/R
injury. Immunoblot assays of NLRP3, ASC, caspase-1, cleaved caspase-1, and IL-1β expressions in the myocardium after I/R. EP, ethyl
pyruvate; NLRP3, nucleotide-binding oligomerization domain-like receptor with a pyrin domain 3; ASC, apoptosis-associated speck-like
protein; IRC, ischemia (30min)-reperfusion (4 h) without treatment; EPpre, EP (50mg/kg) treatment 1 h before ischemia; EPpost, EP
(50mg/kg) treatment upon reperfusion; IL-1β, interleukin-1β. ∗P < 0 05 compared with the sham group; #P < 0 05 compared with the
IRC groups, §P < 0 05 compared between EPpre and EPpost (n = 7, each).
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We next examined whether hypoxia induced activations
of TXNIP and NLRP3 and their interaction compared to
normoxia. Hypoxia clearly increased endogenous TXNIP
and NLRP3 protein levels and their interaction compared
to normoxia in serum-starved H9c2 cells (Figure 6(a)).
When serum-starved cells were exposed to EP under
hypoxia for 24 h, hypoxia-induced increased phosphoryla-
tions of ERK and p38 were mitigated (Figure 6(b)).
To discern EP’s speciﬁc action on the TXNIP-NLRP3
interaction via ERK and p38 under the hypoxic condition,
serum-starved cells were transiently transfected with
pcDNA, Myc-TXNIP, and/or GFP-NLRP3 expression vec-
tors and then treated with EP or inhibitors as indicated
(Figure 6(c)). In TXNIP- and NLRP3-overexpressed cells,
the hypoxia-induced increase in the TXNIP-NLRP3 inter-
action level was signiﬁcantly attenuated by EP at 24h after
exposure to hypoxia. Likewise, U0126, an MEK inhibitor,
and SB203580, a p38 inhibitor, both mitigated the
hypoxia-induced increase in the TXNIP-NLRP3 interac-
tion, yet to a lesser degree than that obtained by EP treat-
ment. These results indicate that EP downregulated
hypoxia-induced TXNIP-NLRP3 interaction, partly via
ERK and p38 pathway.
4. Discussion
In the present study, we could corroborate that EP signiﬁ-
cantly reduced myocardial I/R injury via attenuation of
ROS-related regulatory mechanisms linked to NLRP3
inﬂammasome activation involving NOX4, CTP1A, and
TXNIP. EP’s eﬃcacy for attenuating myocardial infarction
was similar whether it was administered before ischemia or
upon reperfusion. In relation to the MAPK signaling path-
way, EP’s beneﬁcial inﬂuence seems to involve mechanisms
beyond that of inhibiting hypoxia-induced phosphorylations
of ERK and p38.
Although a necessity, restoration of coronary blood
ﬂow following interruption and energy deprivation to the
myocardium inescapably evokes an inﬂammatory response
that mediates further myocardial damage and dysfunction
[17]. Accordingly, extensive research pursued mechanistic
insights related to this sterile inﬂammation after I/R injury





















Figure 5: EP decreased myocardial I/R-induced ERK and p38 phosphorylation. Immunoblot assays of P-ERK, ERK, P-p38, and p38 in the
myocardium after I/R. EP, ethyl pyruvate; IRC, ischemia (30min)-reperfusion (4 h) without treatment; EPpre, EP (50mg/kg) treatment 1 h
before ischemia; EPpost, EP (50mg/kg) treatment upon reperfusion. ∗P < 0 05 compared with the sham group; #P < 0 05 compared with
the IRC groups, (n = 7, each).
























Figure 4: EP attenuated myocardial I/R-induced increases of NOX4, CTP1A, and TXNIP. Immunoblot assays of NOX4, CTP1A, and TXNIP
expressions in the myocardium after I/R. EP, ethyl pyruvate; NOX4, NADPH oxidase-4; CTP1A, carnitine palmitoyltransferase 1A; TXNIP,
thioredoxin-interacting protein; IRC, ischemia (30min)-reperfusion (4 h) without treatment; EPpre, EP (50mg/kg) treatment 1 h before
ischemia; EPpost, EP (50mg/kg) treatment upon reperfusion. ∗P < 0 05 compared with the sham group; #P < 0 05 compared with the IRC
groups (n = 7, each).
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identifying key mediators and thus, endowing potential
therapeutic targets that may enable mitigating myocardial
infarction and enhancing recovery. Among the recognized
proinﬂammatory mediators, recent evidence highlighted
the cardinal role of a macromolecular complex consisting
of NLRP3, ASC, and caspase-1 called the inﬂammasome
in mediating adverse inﬂammatory responses after myo-
cardial I/R [18, 19]. Nonetheless, therapeutic measures
for myocardial infarction aimed at processes related to
attenuating inﬂammasome activation are limited.
Reperfusion after ischemic insult to the myocardium
always accompanies exorbitant ROS formation that induces
further myocardial damage [20–22]. Not surprisingly, ROS
formation and oxidative stress have been shown to be impor-
tant promoters of inﬂammasome activation [23]. In that con-
text, EP seems to be a promising therapeutic agent for
myocardial infarction as it exerts a robust antioxidant eﬀect
[10, 24, 25], not to mention its clinical safety as it is formed
from a naturally occurring metabolic intermediary, pyruvate
[26]. Indeed, EP’s ability to attenuate myocardial I/R injury
has been validated previously [9], while its exact underlying
mechanisms remain largely obscure and evidence is lacking
regarding its association with inﬂammasome regulation
heretofore. Therefore, we aimed to validate mechanistic
insights related to ROS and NLRP3 inﬂammasome regula-
tion and EP’s role in that regard.
As postulated, we could verify that EP’s protective eﬃ-
cacy against myocardial I/R involved mitigation of NLRP3
inﬂammasome activation. Caspase-1 and NLRP3 inﬂamma-
some activation results in increased production of IL-1β, a
powerful proinﬂammatory cytokine, and in a speciﬁc inﬂam-
matory cell death referred to as pyroptosis [5]. Indeed, we
could verify that myocardial I/R provoked a signiﬁcant
increase in the expressions of NLRP3, ASC, and caspase-1,
which comprise the inﬂammasome complex. We also
observed a signiﬁcantly increased production of IL-1β
after I/R in the current study. EP administration, whether
given before ischemia or upon reperfusion, resulted in sig-
niﬁcant attenuation of these essential proteins of inﬂam-
masome and IL-1β compared to the control group. In
intergroup comparisons between the EPpre and EPpost
groups, attenuation of NLRP3, ASC, and caspase-1 expres-
sions by I/R was more signiﬁcant in the EPpre group. Still,
EP’s treatment eﬃcacies in terms of its administration in
temporal relation to I/R seem to be similar as the degree
of IL-1β expression, the end product of inﬂammasome
activation, was similar between the EPpre and EPpost
groups. More deﬁnitely, histologic evidence regarding the
myocardial infarct size and the degree of neutrophil inﬁl-
tration showed similar treatment eﬃcacy of EPpre and
EPpost groups.
To explore detailed mechanistic insights related to ROS
formation and inﬂammasome activation, we further investi-
gated the changes in NOX4, CTP1A, and TXNIP in relation
to I/R and EP treatment. NOX4 serves as a source of cellular
superoxide anions and has been shown to mediate NLRP3
inﬂammasome activation via regulation of a key enzyme
involved in fatty acid oxidation, CTP1A [27]. In that study,
NOX4 deﬁciency yielded reduced CPT1A expression that
consequently resulted in mitigated NLRP3 inﬂammasome
activation in mouse and human macrophages. Thus, the
importance of NOX4 and CPT1A as molecular targets
for therapies aimed at attenuating inﬂammasome activa-
tion has been implicated in diabetes or metabolic diseases
[28–31]. However, there role in myocardial I/R injury,
which involves an acute and far more abundant ROS pro-
duction, in relation to NLRP3 inﬂammasome activation
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Figure 6: EP reduced hypoxia-induced TXNIP-NLRP3 expressions and their interaction partly via ERK and p38 pathway in H9c2
cardiomyocytes. Immunoprecipitation (IP) and immunoblot (IB) assays of TXNIP and NLRP3 expressions, and their interaction in
normoxic (N) or hypoxic (H) conditions in serum-starved H9c2 cardiomyocytes (a). Immunoblot assays of P-ERK, ERK, P-p38, and p38
expressions in a hypoxic condition in serum-starved H9c2 cardiomyocytes treated either with or without EP for 24 h (b). Serum-starved
H9c2 cells were transiently transfected with a Myc-TXNIP and GFP-NLRP3 expression plasmids, incubated in the presence or absence of
EP for 24 h under hypoxia and subjected to IP and IB analysis (c). EP, ethyl pyruvate; TXNIP, thioredoxin-interacting protein; NLRP3,
nucleotide-binding oligomerization domain-like receptor with a pyrin domain 3; U0126, MEK inhibitor; SB203580, p38 inhibitor.
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Likewise, TXNIP, a member of the α-arrestin protein
superfamily, has been shown to bind to thioredoxin thereby
inhibiting its ability to scavenge ROS [15, 32]. Thus, being
closely related to ROS formation and oxidative stress, TXNIP
was identiﬁed to be essential for the activation of the NLRP3
inﬂammasome through direct interaction with NLRP3 via
bondage when freed from thioredoxin, which has been veri-
ﬁed in myocardial I/R models as well [33].
As our data indicate, expression levels of NOX4 and
CTP1A were also signiﬁcantly increased after I/R as with
TXNIP, which could be attenuated by EP treatment regard-
less of its administration timing. These results conﬁrm the
involvement of NOX4 and CTP1A in NLRP3 inﬂammasome
activation for the ﬁrst time.
Next, we tested the association of MAPK with ROS and
inﬂammasome activation in myocardial I/R. ROS formation
was shown to cause the activation of MAPK signaling path-
ways that consequently results in inﬂammasome activation
in experimental models mimicking inﬂammatory diseases
[34]. In myocardial I/R, ROS-triggered MAPK activation
was shown to confer a major role in conveying reperfusion
injury [35, 36], while evidence regarding its association with
inﬂammasome activation is lacking. In the current study,
activations (phosphorylations) of ERK and p38 were sig-
niﬁcantly increased by I/R, which could be attenuated by
EP treatment.
To validate the association of MAPK activation with
TXNIP and NLRP3 inﬂammasome interaction, we per-
formed additional in vitro experiments. Through these, we
conﬁrmed that hypoxia clearly increased the endogenous
interaction of TXNIP and NLRP3 in serum-starved H9c2
cardiomyocytes. Although we could conﬁrm that EP miti-
gated the hypoxia-induced phosphorylations of ERK and
p38 in the in vitro study as well, EP’s distinct action
mechanism does not seem to be speciﬁcally limited to
inhibiting the ROS-triggered MAPK activation. This could
be veriﬁed by our further in vitro study showing that EP
treatment resulted in far more pronounced inhibition of
TXNIP-NLRP3 interaction compared to inhibitors of
MAPK pathways (U0126 (MEK inhibitor) and SB203580
(p38 inhibitor)) in hypoxic cells overexpressed with
TXNIP and NLRP3.
This study entails the following limitations. First,
although we used the same I/R protocols in all experiments,
infarct size measurement by TTC staining has its inherent
limitation of being aﬀected by the duration of reperfusion
[9]. Second, this study did not measure the actual changes
in ROS levels according to I/R and EP treatment while EP’s
antioxidant action in myocardial I/R models, apart from
the addressed mechanisms related to inﬂammasome by the
current study, has been well validated through previous stud-
ies [24, 25]. Third, concerns exist regarding the diﬃculty of
detecting NLRP3 in cardiomyocytes as opposed to microvas-
cular endothelial cells [2]. Likewise, we could detect NLRP3
in H9c2 cardiomyocytes only after a prolonged period of
hypoxia (24 h), which is in agreement with the results of pre-
vious studies [37, 38]. In line with this restriction, we could
not allow an additional period of reoxygenation as cellular
survival was poor in the serum-starved condition, which is
necessary for avoiding serum-induced confounders on intra-
cellular signaling. Thus, our in vitro results only reﬂect the
hypoxic condition, while our main hypothesis could be
clearly validated by our in vivo study.
5. Conclusions
In conclusion, the current study provides primary evidence
that EP’s beneﬁcial eﬀect on myocardial infarction involves
inhibition of NLRP3 inﬂammasome activation. We also
could ﬁrstly conﬁrm that underlying ROS-related mecha-
nisms entail inhibition of hypoxia-induced activations of
NOX4, CTP1A, and MAPK pathways, which would hope-
fully add value to ﬁnding new therapeutic molecular targets
for myocardial infarction.
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